Search research articles
Contact Us
Filters
Showing results (71-80 of 97) with videos related to
Page
of 10
Sort By:
Lancet (London, England)
|
November 13, 2012
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P Giugliano, Nihar R Desai, Payal Kohli, et al.
Journal of the American College of Cardiology
|
February 20, 2007
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial
Piotr Ponikowski, Stefan D Anker, Joanna Szachniewicz, et al.
The Lancet. Diabetes & Endocrinology
|
February 21, 2017
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
Frederick J Raal, G Kees Hovingh, Dirk Blom, et al.
European Heart Journal
|
March 7, 2014
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
Evan A Stein, Robert P Giugliano, Michael J Koren, et al.
European Journal of Heart Failure
|
July 28, 2009
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial
John J V McMurray, Inder S Anand, Rafael Diaz, et al.
The New England Journal of Medicine
|
August 17, 2017
Cognitive Function in a Randomized Trial of Evolocumab
Robert P Giugliano, François Mach, Kenton Zavitz, et al.
Journal of Lipid Research
|
April 23, 2016
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
Frederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
JAMA Cardiology
|
June 14, 2018
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial
Seth S Martin, Robert P Giugliano, Sabina A Murphy, et al.
Clinical Cardiology
|
March 7, 2016
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial
Steven E Nissen, Ricardo E Dent-Acosta, Robert S Rosenson, et al.
The New England Journal of Medicine
|
April 1, 2014
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
Dirk J Blom, Tomas Hala, Michael Bolognese, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 97) with videos related to
Sort By:
Page
of 10
Lancet (London, England)
|
November 13, 2012
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P Giugliano, Nihar R Desai, Payal Kohli, et al.
Journal of the American College of Cardiology
|
February 20, 2007
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial
Piotr Ponikowski, Stefan D Anker, Joanna Szachniewicz, et al.
The Lancet. Diabetes & Endocrinology
|
February 21, 2017
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
Frederick J Raal, G Kees Hovingh, Dirk Blom, et al.
European Heart Journal
|
March 7, 2014
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
Evan A Stein, Robert P Giugliano, Michael J Koren, et al.
European Journal of Heart Failure
|
July 28, 2009
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial
John J V McMurray, Inder S Anand, Rafael Diaz, et al.
The New England Journal of Medicine
|
August 17, 2017
Cognitive Function in a Randomized Trial of Evolocumab
Robert P Giugliano, François Mach, Kenton Zavitz, et al.
Journal of Lipid Research
|
April 23, 2016
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
Frederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
JAMA Cardiology
|
June 14, 2018
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial
Seth S Martin, Robert P Giugliano, Sabina A Murphy, et al.
Clinical Cardiology
|
March 7, 2016
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial
Steven E Nissen, Ricardo E Dent-Acosta, Robert S Rosenson, et al.
The New England Journal of Medicine
|
April 1, 2014
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
Dirk J Blom, Tomas Hala, Michael Bolognese, et al.
Page
of 10